| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England journal of medicine 379 (22), 2108-2121, 2018 | 4172 | 2018 |
| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 2475 | 2020 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1844 | 2022 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1487 | 2020 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1302 | 2017 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The lancet oncology 21 (1), 44-59, 2020 | 1219 | 2020 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 1214 | 2021 |
| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 916 | 2022 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Annals of Oncology 30 (3), 397-404, 2019 | 798 | 2019 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 761 | 2019 |
| Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ... New England Journal of Medicine 387 (3), 217-226, 2022 | 684 | 2022 |
| Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ... Annals of Oncology 30 (3), 405-411, 2019 | 610 | 2019 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 584 | 2018 |
| Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ... Breast Cancer Research 15, 1-37, 2013 | 540 | 2013 |
| Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ... Journal of clinical oncology 36 (9), 884-890, 2018 | 518 | 2018 |
| Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... The Lancet Oncology 22 (4), 499-511, 2021 | 391 | 2021 |
| Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 … P Schmid, R Salgado, YH Park, E Muñoz-Couselo, SB Kim, J Sohn, SA Im, ... Annals of Oncology 31 (5), 569-581, 2020 | 370 | 2020 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 348 | 2020 |
| Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant JM Spoerke, S Gendreau, K Walter, J Qiu, TR Wilson, H Savage, J Aimi, ... Nature communications 7 (1), 11579, 2016 | 328 | 2016 |
| Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study P Schmid, Y Nagai, R Agarwal, B Hancock, PM Savage, NJ Sebire, ... The Lancet 374 (9683), 48-55, 2009 | 322 | 2009 |
